Noumis 737m Buyout|A 12-Cent Share Price

The $0.1234 exit from a $737m deal

Noumi shareholders have just been offered twelve point three four cents for every share they hold. The company that owns the MilkLab almond milk carton on your supermarket shelf, along with Australia's Own and So Natural, is being taken private for what its own board calls a seven hundred and thirty seven million dollar deal. Those two numbers describe almost different companies. A single cent-denominated share price sitting inside a headline figure in the hundreds of millions is the first thing that should stop a shareholder cold.

The gap resolves once the deal is broken into its parts. Arrovest, the private vehicle of the billionaire Perich family, is paying about thirty four point two million dollars for all the equity it doesn't already own. The rest of the seven hundred and thirty seven million dollar figure is debt — roughly seven hundred and three million dollars in convertible notes and facilities that Noumi already owed before Arrovest offered a cent. Shareholders are not being handed a slice of a seven hundred million dollar prize. They are being handed the small residual left after the debt is accounted for.

On the surface the offer even looks reasonable: twelve point two per cent above the last closing price, thirty per cent above the thirty-day average. But a premium calculated against a stock that had already been sold down by a market pricing in a looming debt crisis is a premium over a depressed base, not evidence the underlying business is worth little more than thirty four million dollars.

Why the board said yes to a record year's low-ball

What makes the low equity value harder to square is the timing. Noumi's preliminary FY26 numbers point to adjusted operating earnings of sixty one to sixty three million dollars, up from fifty seven point four million the year before. Dairy and Nutritionals revenue rose almost twelve per cent. Plant-based milk revenue hit a record. This is not a company in earnings freefall being rescued at any price — it is a company recovering, being sold at the bottom of its own trading range.

The independent board committee's own words are that Arrovest's proposal is, quote, the only credible and executable pathway identified that addresses the note maturity as part of a coordinated debt and equity solution. That is a strong claim, and the articles do not detail which alternative buyers, recapitalisation structures, or note extensions were tested and rejected across the year-long review — only that none delivered comparable shareholder value. A unanimous recommendation resting on an unspecified process is the buried assumption a shareholder is being asked to accept on faith.

So the paradox sharpens: an earnings recovery is being used to justify optimism about Noumi's future in Arrovest's own statement, while the same year's numbers are used by the board to justify accepting a token cash-out. Both cannot be the fair read of the same set of facts — either the recovery is real and worth more than thirty four million dollars, or the debt overhang makes the recovery irrelevant to what shareholders can actually extract.

The May 2027 clock and the vote that decides it

The clock forcing this deal is a six hundred and ten million dollar mandatory redemption of convertible notes due in May twenty twenty seven. Noumi says it spent a year testing a whole-of-company sale, individual asset sales, recapitalisation, refinancing, and note-term amendments, and found no alternative capable of repaying that debt on acceptable terms. Arrovest has separately agreed to buy thirty eight and a half per cent of the outstanding notes from institutional holders at a discount, lifting its own note holding toward eighty two per cent — control of both the equity and the debt side of the table.

Shareholders vote on the scheme in November, and the deal is conditional on an independent expert concluding it is fair and reasonable to security holders — a report that has not yet been published in the articles reviewed here. That report, not the board's recommendation alone, is the next concrete checkpoint that can validate or undercut the twelve-cent price. A holder's real decision point is not today's headline, it is what that expert publishes before the vote.

For a current holder, rejecting the scheme without a superior proposal on the table means staying exposed to a company that has already said it found no other way to meet a debt wall two years out — that is the trap condition. For a holder or a watcher who believes the earnings recovery is being underpriced, an independent expert's report finding the offer inadequate, or a rival bid emerging before the November meeting, is the entry-setup condition that would break the current price as the ceiling. Until the expert's report is published, that is the single figure to watch before deciding which way this resolves.